Webinar: ACR/CHEST ILD Guidelines in Practice| Video: All the Lonely People

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Professional Topics

Subcategories:AwardsCareer DevelopmentEthicsInterprofessional PerspectiveLegislation & AdvocacyPresident's PerspectiveProfilesRheuminations

I Am an Advocate

Deanna Sanchez Yamamoto, NP  |  

I have never considered myself to be a political person, much less an “advocate,” which is why I was surprised to become an ARHP advocacy committee member.

What a Bold Vision and Dedication Can Achieve

Leslie Crofford, MD  |  

Over the past two years, you have heard us talking a lot about Within Our Reach: Finding a Cure for Rheumatoid Arthritis, the Research and Education Foundation (REF) campaign to raise and award funds for investigator-initiated research to find a cure for rheumatoid arthritis (RA).

Letters to the Editor

  |  

I read with interest Dr. Fox’s perspective in the June issue of The Rheumatologist [TR] regarding ghost writing in medical research. Dr. Fox is all for integrity in research (who isn’t?); nevertheless, he takes to task some of the people (Ross et al and the editors of the Journal of the American Medical Association [JAMA]) who write about the corrupting influence of industry on physicians, including those in academics [JAMA 2008;299(15):1800-1812]. Part of his motivation may be to defend members of ACR who have been involved in the activity of ghostwriting and guest editing. This approach may play well to readers of The Rheumatologist, but it would seem that Dr. Fox should address his concerns to the editors of JAMA. That way, the authors of the article could offer a rebuttal to Dr. Fox’s concerns and assertions, and we all could get closer to the truth about this important issue.

I Am an Advocate

Charles King, MD  |  

It was the best of times, it was the worst of times; it was the age of wisdom, it was the age of foolishness.” Cliché perhaps, but certainly fitting in describing the practice of rheumatology of late. We have been blessed with a widening array of therapies with which to treat rheumatologic illnesses. The advent of the biological era promises even greater potential for meaningful reductions in disability and death from these diseases.